(Q38979939)

English

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

0 references

1 reference

based on heuristic

inferred from title

7

object named as

David C Linch

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

6

object named as

Rosemary E Gale

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Koremu Meja

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Chloe Stengel

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Rob Sellar

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dennis Huszar

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Barry R Davies

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Asim Khwaja

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

30 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

167

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

69-79

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

mTOR signaling in growth control and disease

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Tumour heterogeneity and cancer cell plasticity

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

The PIM family of serine/threonine kinases in cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

For better or for worse: the role of Pim oncogenes in tumorigenesis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Delving deeper: MCL-1's contributions to normal and cancer biology

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Activating alleles of JAK3 in acute megakaryoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13013

21 January 2018

Identifiers

10.1111/BJH.13013

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38979939&oldid=1800537571"